Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
6.660
Open
6.620
VWAP
6.59
Vol
2.49K
Mkt Cap
60.19M
Low
6.5285
Amount
16.41K
EV/EBITDA(TTM)
26.59
Total Shares
7.81M
EV
65.76M
EV/OCF(TTM)
43.46
P/S(TTM)
2.07
ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).
Show More
Valuation Metrics
The current forward P/E ratio for ImmuCell Corp (ICCC.O) is -60.55, compared to its 5-year average forward P/E of -59.36. For a more detailed relative valuation and DCF analysis to assess ImmuCell Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-59.36
Current PE
-60.55
Overvalued PE
-40.40
Undervalued PE
-78.32
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
3.11
Current PS
3.33
Overvalued PS
4.01
Undervalued PS
2.21
Financials
Annual
Quarterly
FY2025Q1
YoY :
+11.16%
8.07M
Total Revenue
FY2025Q1
YoY :
-472.48%
1.12M
Operating Profit
FY2025Q1
YoY :
-430.46%
1.45M
Net Income after Tax
FY2025Q1
YoY :
-366.67%
0.16
EPS - Diluted
FY2025Q1
YoY :
+257.54%
1.24M
Free Cash Flow
FY2025Q1
YoY :
+31.46%
41.58
Gross Profit Margin - %
FY2025Q1
YoY :
-122.16%
2.89
FCF Margin - %
FY2025Q1
YoY :
-397.51%
17.94
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
ICCC News & Events
Events Timeline
2025-07-09 (ET)
2025-07-09
08:09:55
Immucell reports preliminary unaudited Q1 revenue $6.4M vs. $5.5M last year
2025-06-25 (ET)
2025-06-25
08:10:57
Immucell embarks on CEO succession planning process
2025-04-08 (ET)
2025-04-08
16:20:52
Immucell reports preliminary Q1 revenue $8.1M vs. $7.3M last year
Sign Up For More Events
Sign Up For More Events
News
6.5
07-18NASDAQ.COMTop Research Reports for Alphabet, Oracle & Shell
5.0
06-25NASDAQ.COMImmuCell Begins Search For New CEO As Michael Brigham To Retire Next Year
5.0
06-25NewsfilterImmuCell Embarks on CEO Succession Planning Process
Sign Up For More News
People Also Watch
MSAI
MultiSensor AI Holdings Inc
0.780
USD
-4.76%
AHT
Ashford Hospitality Trust Inc
6.320
USD
+0.32%
OMCC
Old Market Capital Corp
5.510
USD
-4.17%
ROLR
High Roller Technologies Inc
2.200
USD
-1.35%
WKEY
Wisekey International Holding AG
5.360
USD
+1.13%
DUOT
Duos Technologies Group Inc
6.060
USD
-4.57%
BYFC
Broadway Financial Corp
7.870
USD
-1.63%
IVVD
Invivyd Inc
0.770
USD
-3.51%
NRXP
NRX Pharmaceuticals Inc
2.320
USD
-7.94%
MODD
Modular Medical Inc
0.723
USD
-3.47%
FAQ
What is ImmuCell Corp (ICCC) stock price today?
The current price of ICCC is 6.66 USD — it has increased 0 % in the last trading day.
What is ImmuCell Corp (ICCC)'s business?
What is the price predicton of ICCC Stock?
What is ImmuCell Corp (ICCC)'s revenue for the last quarter?
What is ImmuCell Corp (ICCC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for ImmuCell Corp (ICCC)'s fundamentals?
How many employees does ImmuCell Corp (ICCC). have?